Skip to content

Study on the efficacy of online cognitive therapy to enhance rTMS in the treatment of depression

Study on the efficacy of online cognitive therapy to enhance rTMS in the treatment of depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074500
Enrollment
Unknown
Registered
2023-08-08
Start date
2023-08-01
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

major depressive disorder

Interventions

rTMS + online CBT:rTMS combined with online cognitive-behavioral therapy
rTMS+ Cognitive correction therapy:rTMS combined with cognitive correction therapy

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: a)Patients diagnosed with major depressive disorder in Mini-International Neuropsychiatric Interview (MINI Chinese) were eligible for either first episode or relapse. b) Hamilton Depression Scale (HAMD-17) score =14 during the screening and baseline periods; c) Outpatient or inpatient patients aged 18-65 years (including 18 and 65 years), regardless of gender; d) Primary school education or above, able to understand the research content; e) Voluntarily participate in the study and sign the informed consent. f) There was no drug change in the past four weeks, and the type and dose of drug therapy remained unchanged during the study period.

Exclusion criteria

Exclusion criteria: a) MINI Chinese version diagnosed with current/past/lifetime: bipolar disorder, substance abuse, post-traumatic stress disorder, schizophrenia, personality disorder, dissociative conversion disorder, psychosis and other disorders. b) For those at high risk of suicide, the HAMD-17 suicide risk entry is greater than or equal to 3 points. c) mental retardation, dementia and other cognitive disorders. d) Serious physical diseases, brain organic diseases, neurological diseases, etc. e) Presence of a metallic foreign body above the chest. f) received systemic modified electroconvulsive therapy (MECT) or transcranial magnetic stimulation therapy (TMS), deep brain stimulation therapy (DBS), or deviant nerve stimulation therapy (VNS) in the 3 months prior to screening g) Persons currently undergoing psychotherapy.

Design outcomes

Primary

MeasureTime frame
HAMD-17;functional near-infrared spectroscopy;functional magnetic resonance imaging;

Secondary

MeasureTime frame
PHQ-9;CGI-S;

Countries

China

Contacts

Public ContactHongru Zhu

West China Hospital of Sichuan University

zhuhongru@wchscu.cn+86 189 8060 3592

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026